Hong Sang

Array ( [id] => 18077410 [patent_doc_number] => 20220403022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => Anti-TIGIT Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/774685 [patent_app_country] => US [patent_app_date] => 2020-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111814 [patent_doc_number] => 20210292411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => METHOD OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/089255 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870106 [patent_doc_number] => 20210163573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => IDENTIFICATION OF IMMUNOGENIC MHC CLASS II PEPTIDES FOR IMMUNE-BASED THERAPY [patent_app_type] => utility [patent_app_number] => 17/086669 [patent_app_country] => US [patent_app_date] => 2020-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17086669 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711961 [patent_doc_number] => 20210079108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) [patent_app_type] => utility [patent_app_number] => 17/079075 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21416 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17079075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16718620 [patent_doc_number] => 20210085767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/076535 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18717892 [patent_doc_number] => 11795223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia [patent_app_type] => utility [patent_app_number] => 17/072681 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 15 [patent_no_of_words] => 60359 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17098159 [patent_doc_number] => 20210285950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER [patent_app_type] => utility [patent_app_number] => 17/069666 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17069666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050966 [patent_doc_number] => 20240092935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTI-TN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/767766 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749974 [patent_doc_number] => 20210101983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => ANTI-TREM1 ANTIBODIES AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 17/066401 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18212917 [patent_doc_number] => 20230059181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => IgE Antibody with Fcgamma Receptor binding [patent_app_type] => utility [patent_app_number] => 17/764850 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17764850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16726583 [patent_doc_number] => 20210093730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => BIOMARKERS FOR ANTIBODY-DRUG CONJUGATE MONOTHERAPY OR COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/038868 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19608909 [patent_doc_number] => 12157775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-03 [patent_title] => Methods of using bispecific antigen-binding constructs targeting HER2 [patent_app_type] => utility [patent_app_number] => 17/033441 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 84 [patent_figures_cnt] => 130 [patent_no_of_words] => 53313 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 335 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18970470 [patent_doc_number] => 20240050562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO [patent_app_type] => utility [patent_app_number] => 17/766280 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17756273 [patent_doc_number] => 11396557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Bispecific antibody or antibody mixture with common light chains [patent_app_type] => utility [patent_app_number] => 17/022545 [patent_app_country] => US [patent_app_date] => 2020-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 28 [patent_no_of_words] => 18281 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 296 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17022545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210744 [patent_doc_number] => 11999792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Antibody therapeutics that bind CD38 [patent_app_type] => utility [patent_app_number] => 17/016104 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 23050 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628786 [patent_doc_number] => 20210047439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => DLL3 BINDING PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/999773 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47104 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18779119 [patent_doc_number] => 11820813 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-21 [patent_title] => Anti-neurotensin long fragment antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/994770 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 13 [patent_no_of_words] => 16141 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256148 [patent_doc_number] => 12428491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => PSMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 16/994953 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 48773 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16994953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18666303 [patent_doc_number] => 11773181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Anti-survivin antibodies for cancer therapy [patent_app_type] => utility [patent_app_number] => 16/990622 [patent_app_country] => US [patent_app_date] => 2020-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 10255 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657457 [patent_doc_number] => 20210054093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => Novel CD47 Monoclonal Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/989702 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 352 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989702 [rel_patent_id] =>[rel_patent_doc_number] =>)